Transdermal testosterone administration in hypogonadal men: Comparison of pharmacokinetics at different sites of application and at the first and fifth days of application

Journal of Clinical Pharmacology

Volumn 37, Issue 12, 1997, Pages 1129-1138

  Yu, Zhiling ^a   Gupta, Suneel K ^a   Hwang, Stephen S ^a   Cook, David M ^b   Duckett, Melvin J ^c   Atkinson, Linda E ^c  

^a ALZA CORPORATION   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Prtners in Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ESTRADIOL; PLACEBO; TESTOSTERONE;

ADULT; AGED; AREA UNDER THE CURVE; ARM; ARTICLE; BACK; BUTTOCK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DOSAGE FORM; DRUG METABOLISM; GEL; HUMAN; HYPOGONADISM; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031405892     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04297.x     Document Type: Article

References (14)

1. Bain J: Male hypogonadism. Comp Ther 1983;9:17-24.
2. Mooradian AD, Molley JE, Kolerman SG: Biological actions of androgens. Endocrinol Rev 1987;8:l-28.
3. Bagatelle CJ, Bremner WJ: Androgens in men: uses and abuses. N Engl J Med 1996; 334:707-714.
4. Bhasin S: Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992;74:1221-1225.
5. Konowich PA (éd.): Physician's Desk Reference. Fifty-first edition. Montvale, NJ: Medical Economics Data Production, 1997.
6. Cunningham GR, Cordero E, Thornby JI: Testosterone replacement with transdermal therapeutic systems: physiological serum testosterone and elevated dihydrotestosterone levels. JAMA 1989;2G1:2525-2530.
7. Findlay JC, Place V, Snyder PJ: Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab 1989;G8:3G9-373.
8. Findlay JC, Place VA, Snyder PJ: Transdermal delivery of testosterone. J Clin Endocrinol Metab 1987;64:266-268.
9. Korenman SG, Viosca S, Garza D, Guralnik M, Place V, Campboll P, Davis SS: Androgen therapy of hypogonadal men with transcrotal testosterone systems. Am J Med 1987;83:471-478.
10. Place VA, Nichols KG: Transdermal delivery of testosterone with Testoderm to provide a normal circadian pattern of testosterone. Ann N Y Acad Sci 1991:618:441-449.
11. Place VA, Atkinson L, Prather DA, Trunnell N, Yates FE: Transdermal testosterone replacement through genital skin. In, Nieschlag E, Behrc HM (eds.): Testosterone: Action, Deficiency, Substitution. Heidelberg: Springer-Verlag, 1990:105-181.
12. Meikle AW, Arvcr S, Dobs AS, Sanders SW, Rajaram L, Mazer NA: Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site-a clinical research center study. J Clin Endocrinol Metab 1996:81:1832-1840.
13. Yu Z, Hwang SS, Gupta SK: DeMonS: a new deconvolution method for estimating drug absorbed at different time intervals and/or drug disposition model parameters using a monotonie cubic spline. Biopharm Drug Dispos 1997; 18:475-487.
14. Bremner WJ, Vitiello MV, Prinz PN: Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983:56:1278-1281.